ArticleFrontiers in oncology2026
Case Report: Supraorbital keyhole resection of IDH-mutant grade 3 astrocytoma of the medial orbitofrontal region.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: High-grade gliomas located in the medial orbitofrontal region present significant surgical challenges due to their deep location and proximity to critical neurovascular structures. While the supraorbital eyebrow approach is widely used for extra-axial skull base lesions, its application to intra-axial high-grade gliomas remains less frequently reported. Case description: We report the case of a 47-year-old female diagnosed with an isocitrate dehydrogenase (IDH)-mutant World Health Organization Grade 3 astrocytoma located in the medial orbitofrontal cortex. The patient underwent gross total resection via a minimally invasive supraorbital trans-eyebrow craniotomy. Early postoperative MRI performed within 72 hours confirmed gross total resection without residual contrast-enhancing tumor. Histopathological examination demonstrated microvascular proliferation consistent with Grade 3 astrocytoma, and molecular analysis confirmed IDH mutation. The patient subsequently received standard adjuvant radiochemotherapy with temozolomide. Follow-up demonstrated preserved neurological function and high cosmetic satisfaction. Conclusion: This case illustrates that, in carefully selected patients, the supraorbital keyhole approach can achieve oncologically adequate resection of medial orbitofrontal IDH-mutant high-grade gliomas while minimizing surgical morbidity and optimizing cosmetic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.